About this trial
Bempedoic acid pregnancy surveillance program
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Primary care
Trial design
Cohort
Other
Treatments tested in this trial
Bempedoic Acid
DrugBempedoic Acid 180 MG
Bempedoic Acid / Ezetimibe
DrugBempedoic Acid 180 MG / Ezetimibe 10 MG
Treatment groups
Trial outcomes
Primary outcomes
Major congenital malformations (MCM)
An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention (CDC 2019a). MCMs will be defined and coded with criteria specified by US CDC Metropolitan Atlanta Congenital Defects Program (MACDP).
Secondary outcomes
Minor congenital malformation
An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual (CDC 2019a). The surveillance program defines and codes minor congenital malformations with criteria specified as defined by CDC (CDC 2017).
Spontaneous abortion
An involuntary fetal loss or the expulsion of the products of conception occurring at \< 20 gestational weeks.
Stillbirth
As defined by the American College of Obstetricians and Gynecologists (ACOG), an involuntary fetal loss occurring at ≥ 20 gestational weeks or, if gestational age is unknown, a fetus weighing ≥ 350 g.
Elective termination
A voluntary fetal loss or interruption of pregnancy, including pregnancy termination that occurs electively, to preserve maternal health or due to fetal abnormalities.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.